KOBIO, the first web-based Korean biologics registry operated with a unified platform among distinct disease entities

Jinhyun Kim, Jung Hee Koh, Sung Jae Choi, Chan Hong Jeon, Seung Ki Kwok, Seong Kyu Kim, Chan Bum Choi, Jaejoon Lee, Changhoon Lee, Eon Jeong Nam, Yong Beom Park, Shin Seok Lee, Tae Hwan Kim, Sung Hwan Park, Jung Yoon Choe, Eun Mi Koh, Dae Hyun Yoo, Yeong Wook Song, Hyoun Ah Kim, Kichul Shin

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

The KOrean College of Rheumatology BIOlogics and targeted therapy (KOBIO) registry is a nationwide observational cohort that captures detailed data on exposure of patients to biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs). This registry was launched in December 2012 with an aim to prospectively investigate clinical manifestations and outcomes of patients with rheumatoid arthritis (RA), ankylosing spondylitis, and psoriatic arthritis who initiated a biologic or targeted synthetic DMARD or switched to another. Demographic data, disease activity, current treatment, adverse events, terms based on Medical Dictionary for Regulatory Activities, and so on are registered for patients who are then followed up annually in a web-based unified platform. The KOBIO registry also recruits and collects data of patients with RA on conventional DMARDs for comparison. As of today, more than 5,500 patients were enrolled from 47 academic and community Rheumatology centers across Korea. The KOBIO registry has evolved to become a powerful database for clinical research to improve clinical outcomes and quality of treatment.

Original languageEnglish
Pages (from-to)176-182
Number of pages7
JournalJournal of Rheumatic Diseases
Volume28
Issue number4
DOIs
StatePublished - 2021

Bibliographical note

Funding Information:
We would like to thank Kimmie Hyrich, Kath Watson, Ms. Kim HJ and the KCR administrative staff, current and previous members of the study team, INFOrang, Ltd., and the generous donation of biopharmaceutical companies that made KOBIO possible.

Publisher Copyright:
Copyright © 2021 by The Korean College of Rheumatology.

Keywords

  • Ankylosing spondylitis
  • Biological products
  • Psoriatic arthritis
  • Registries
  • Rheumatoid arthritis

Fingerprint

Dive into the research topics of 'KOBIO, the first web-based Korean biologics registry operated with a unified platform among distinct disease entities'. Together they form a unique fingerprint.

Cite this